Get started
Author

Tina M. Woo

Observed names: T. Woo, Tina M Woo, Tina Woo
OpenAlex ID: A5036889586
Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
2007 · Susan D. Demo, Christopher J. Kirk, et al. · Cancer Research · 678
PDF
Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)
2009 · Han-Jie Zhou, Monette A. Aujay, et al. · Journal of Medicinal Chemistry · 272
Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib
2012 · Zhengping Wang, Jinfu Yang, et al. · Drug Metabolism and Disposition · 144
Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency.
2010 · A. Z. Badros, R. Vij, et al. · Journal of Clinical Oncology · 21
A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.
2011 · K. P. Papadopoulos, D. S. Mendelson, et al. · Journal of Clinical Oncology · 20
Biochemical and Cellular Characterization of the Novel Proteasome Inhibitor PR-171.
2005 · Susan D. Demo, Tonia J. Buchholz, et al. · Blood · 13
A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation.
2024 · Amita Patnaik, Meredith Pelster, et al. · Journal of Clinical Oncology · 12
PDF
Multicenter Phase I Studies To Evaluate the Safety, Tolerability, and Clinical Response to Intensive Dosing with the Proteasome Inhibitor PR-171 in Patients with Relapsed or Refractory Hematological Malignancies.
2006 · Owen A. O’Connor, Robert Z. Orlowski, et al. · Blood · 12
Phase I Study of Carfilzomib in Patients (Pts) with Relapsed and Refractory Multiple Myeloma (MM) and Varying Degrees of Renal Insufficiency.
2009 · Ashraf Z. Badros, Ravi Vij, et al. · Blood · 11
Phase 1b Evaluation of the Safety and Efficacy of a 30-Minute IV Infusion of Carfilzomib In Patients with Relapsed and/or Refractory Multiple Myeloma
2010 · Kyriakos Papadopoulos, David Samuel diCapua Siegel, et al. · Blood · 6
Pharmacokinetics, Pharmacodynamics and Anti-Tumor Efficacy of PR-171, a Novel Inhibitor of the 20S Proteasome.
2005 · Christopher J. Kirk, Mark K. Bennett, et al. · Blood · 3
Potent Inhibition of Multiple Proteasome Subunits by Carfilzomib in Multiple Myeloma and Solid Tumor Patients
2011 · Susan J Lee, Tina M Woo, et al. · Blood · 1
Anti-Tumor Activity of Immunoproteasome Selective Inhibitors.
2007 · Francesco Parlati, Monette Aujay, et al. · Blood · 1
Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders.
2006 · Francesco Parlati, Monette A. Aujay, et al. · Blood · 1
Supplementary Figure 1 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
2023 · Susan D. Demo, Christopher J. Kirk, et al.
PDF
Data from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
2023 · Susan D. Demo, Christopher J. Kirk, et al.
Data from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
2023 · Susan D. Demo, Christopher J. Kirk, et al.
Supplementary Figure 1 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
2023 · Susan D. Demo, Christopher J. Kirk, et al.
Supplementary Figure 2 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
2023 · Susan D. Demo, Christopher J. Kirk, et al.
PDF
Supplementary Figure 2 from Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
2023 · Susan D. Demo, Christopher J. Kirk, et al.
Pharmacodynamic, pharmacokinetic and anti-tumor properties of orally bioavailable inhibitors of the 20S proteasome
2007 · Jing Jiang, Monette Aujay, et al. · Molecular Cancer Therapeutics
Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity.
2006 · Susan D. Demo, Monette A. Aujay, et al. · Blood
Pharmacologic Evaluation of Orally Bioavailable Inhibitors of the 20S Proteasome.
2006 · Christopher J. Kirk, Monette A. Aujay, et al. · Blood
Works count: 24
Citation count: 1,195
H-index: 9
I10-index: 9
Year
Topic
Type